Cannabis Use Disorder

Understanding Cannabis Use Disorder

What CUD Is

CUD is a DSM-5 diagnosis applied when a pattern of cannabis use produces impaired control, social impairment, risky use, and pharmacological dependence over a 12-month period. It is graded mild, moderate, or severe by criteria count. Like other substance use disorders, it sits on a continuum — many people use cannabis occasionally without meeting criteria; some develop substantial dependence and impairment.

What CUD Is Not

CUD is not defined by legality. Cannabis is legal for adult use in many US states and several countries; this changes the social context of use but not the existence of the disorder. CUD is also not defined by quantity alone — a daily user who functions well and meets no DSM criteria does not have CUD; an episodic user whose use produces serious consequences and loss of control may.

"It's Just Weed" — The Cultural Lag

The popular image of cannabis as benign reflects the cannabis of decades past, with average THC content of a few percent. Modern flower commonly tests at 20% or more, and concentrates can exceed 80%. The clinical picture of CUD today reflects exposure to a substantially different drug than the one most cultural narratives reference. This matters for users, families, and clinicians: dismissing concerns about cannabis on the basis of older norms ignores current data.

Who Develops CUD

CUD occurs across demographics but risk is concentrated among those who start young, use daily or near-daily, use high-potency products, and have co-occurring psychiatric conditions. Family history, trauma, untreated anxiety or ADHD, and social environments where heavy use is normative all increase risk.

DSM-5 Diagnostic Criteria

CUD requires 2 or more of the following 11 criteria within a 12-month period:

Impaired Control

1. Cannabis taken in larger amounts or over a longer period than intended
2. Persistent desire or unsuccessful efforts to cut down or control use
3. Great deal of time spent obtaining, using, or recovering
4. Craving — strong desire or urge to use cannabis

Social Impairment

5. Recurrent use resulting in failure to fulfill major role obligations
6. Continued use despite persistent social or interpersonal problems
7. Important activities given up or reduced

Risky Use

8. Recurrent use in physically hazardous situations (driving, machinery)
9. Continued use despite persistent physical or psychological problems caused or worsened by cannabis

Pharmacological

10. Tolerance — markedly increased amounts needed, or diminished effect with the same amount
11. Withdrawal — characteristic withdrawal syndrome, or cannabis taken to relieve or avoid withdrawal

Severity

• Mild: 2–3 criteria
• Moderate: 4–5 criteria
• Severe: 6 or more criteria

Modern High-Potency Cannabis

What "Potency" Means

Potency refers to the concentration of THC (delta-9-tetrahydrocannabinol), the primary psychoactive cannabinoid. Average THC content of cannabis flower in the 1990s was roughly 3–4%. Modern flower commonly contains 15–25% or more. Concentrates — waxes, shatters, oils, vape cartridges — can exceed 70–90%.

Why It Matters Clinically

• Higher peak THC levels are associated with greater acute impairment
• High-potency products are associated with elevated rates of CUD
• Higher-potency exposure is associated with elevated psychosis risk in vulnerable users
• Concentrate use produces tolerance more quickly and intensifies withdrawal

CBD vs. THC

Cannabidiol (CBD) is the second most studied cannabinoid. It does not produce the intoxicating effects of THC. Some products are marketed as "low-THC, high-CBD"; others are predominantly THC. The clinical picture of CUD is driven by THC exposure, not by CBD content. Some evidence suggests CBD may modestly mitigate THC's adverse effects, but products vary widely and labeling is inconsistent.

Routes and Products

• Flower (smoked, vaporized)
• Edibles (delayed onset, longer duration, higher risk of unintended overconsumption)
• Concentrates (dabs, vape cartridges, very high potency)
• Tinctures and oils

Cannabis Withdrawal Syndrome

Cannabis withdrawal was added as a DSM-5 diagnosis to correct a long-standing clinical blind spot. It is real, well-documented, and an important driver of relapse.

DSM-5 Cannabis Withdrawal Criteria

Withdrawal develops within approximately 1 week after stopping heavy, prolonged use and includes three or more of the following:

• Irritability, anger, or aggression
• Nervousness or anxiety
• Sleep difficulty (insomnia, disturbing dreams)
• Decreased appetite or weight loss
• Restlessness
• Depressed mood
• At least one physical symptom: abdominal pain, shakiness/tremors, sweating, fever, chills, headache

Course

Symptoms typically begin within 24–72 hours of stopping, peak in the first week, and largely resolve within 2 weeks, although sleep disturbance and irritability can persist longer. Withdrawal is uncomfortable but not medically dangerous.

Clinical Significance

Withdrawal-driven relapse is one of the central maintaining mechanisms in CUD. Many users believe they "can't sleep without it" — what they are experiencing is withdrawal, not a fixed insomnia. Sleep and mood normalize over weeks of abstinence for most.

Health and Psychiatric Effects

Cognitive

Acute cannabis intoxication impairs attention, working memory, executive function, and motor coordination. Chronic heavy use, particularly when started in adolescence, is associated with measurable cognitive effects on memory and processing speed. The reversibility of these effects with abstinence is partially supported but incomplete, especially for adolescent-onset heavy use.

Mental Health

• Anxiety disorders (paradoxically, cannabis can both relieve and worsen anxiety)
• Depression
• Increased risk of psychotic disorders, particularly with high-potency use and early initiation
• Worsened course of bipolar disorder
• Cannabis-induced anxiety and psychotic disorders are formally recognized diagnoses

Respiratory

• Chronic bronchitis with smoked use
• Increased respiratory infections
• Vaping-associated lung injury has been documented with certain illicit cartridges

Cardiovascular

• Increased heart rate
• Elevated risk of myocardial infarction in the hour following use, particularly in those with underlying disease
• Possible increased stroke risk with heavy use

Cannabinoid Hyperemesis Syndrome (CHS)

A paradoxical syndrome in some chronic users — cyclic vomiting, abdominal pain, and compulsive hot bathing for symptom relief. CHS resolves with cessation but is frequently missed and misdiagnosed as cyclic vomiting syndrome or psychiatric illness.

Driving

Cannabis significantly impairs driving performance. The effect compounds dangerously with alcohol. Acute impairment lasts hours but lingering effects on attention can extend longer, particularly with high-dose use.

Pregnancy

Prenatal cannabis exposure is associated with adverse outcomes including low birth weight and neurodevelopmental effects. There is no established safe level of use in pregnancy. Cannabis is not an evidence-based treatment for pregnancy-associated nausea.

Cannabis and Psychosis Risk

The Evidence

The relationship between cannabis and psychotic disorders is one of the most studied issues in addiction psychiatry. The current weight of evidence supports a causal contribution of cannabis use to the onset of psychotic disorders in vulnerable individuals — not in everyone, but in a clinically meaningful subset.

What Increases the Risk

• Initiation in early adolescence
• Daily or near-daily use
• High-potency products
• Genetic risk for psychosis (family history of schizophrenia or related conditions)
• Childhood trauma

Cannabis-Induced Psychosis

Acute cannabis-induced psychotic disorders are recognized in DSM-5. They can resolve with abstinence but in some individuals progress to enduring psychotic disorders (schizophrenia spectrum). The exact proportion is debated; the risk is real enough to warrant clinical screening and discussion.

For People with Family History of Psychosis

For individuals with a personal or strong family history of schizophrenia or related psychotic disorders, current evidence is sufficient to recommend avoiding cannabis — particularly high-potency products — entirely.

Causes and Risk Factors

Genetic

Heritability of CUD is approximately 50–70%. Genetic factors influence cannabinoid receptor function, reward sensitivity, and the broader vulnerability to substance use disorders.

Age of Initiation

Early initiation (before 16) is one of the strongest predictors of progression to CUD. The adolescent brain — particularly the prefrontal cortex — is still developing into the mid-20s, and chronic exposure during this period appears to produce more lasting changes than equivalent use in adulthood.

Co-occurring Psychiatric Conditions

• Anxiety disorders (cannabis is often used for self-medication)
• Depression
• ADHD
• PTSD
• Insomnia (cannabis is widely used as a sleep aid; long-term, it tends to worsen sleep)

Trauma

Adverse childhood experiences and unresolved trauma are strongly associated with CUD risk. Cannabis use as emotional regulation in the context of trauma is a common clinical pathway.

Social

• Peer norms and family environment
• Ease of access and price
• Cultural narratives that minimize risk
• Increased availability with legalization

Assessment and Diagnosis

Screening

• Cannabis Use Disorders Identification Test (CUDIT-R): 8-item self-report
• TAPS: Primary care substance use screen
• NIDA Quick Screen: General brief screen

Clinical Interview

Assessment covers quantity, frequency, product type and potency, route, age of initiation, pattern, consequences, tolerance, withdrawal, prior treatment, co-occurring substance use, psychiatric history, and family history of psychotic disorders.

Medical Evaluation

Urine drug testing detects cannabis for days to weeks, depending on frequency of use. Liver function, mental status, and cardiovascular evaluation are reasonable in heavy users.

Differential Diagnosis

• Primary anxiety, depressive, or psychotic disorder
• Other substance use disorders
• Cannabis-induced psychiatric disorders (anxiety, psychosis)
• Cannabinoid hyperemesis syndrome (often missed)

Treatment Approaches

Behavioral Therapies

Behavioral therapies are the first-line evidence-based treatment for CUD. No medication is FDA-approved.

Cognitive Behavioral Therapy

CBT for CUD targets triggers, beliefs about cannabis, cravings, and coping skills. Typical course is 8–14 sessions. Meaningful reductions in use are common.

Motivational Enhancement Therapy

Brief, structured intervention building motivation for change. Often used in 2–4 sessions, sometimes alone and sometimes as the first phase of a longer treatment.

Contingency Management

Tangible rewards for verified cannabis-free urine. Strong evidence in research settings; broader implementation is uneven.

Combined Approaches

Combinations of MET + CBT + contingency management produce the strongest outcomes in clinical trials.

Pharmacotherapy

No FDA-approved medication exists. Several have been studied with modest or inconsistent results:

• N-acetylcysteine — modest evidence in adolescents
• Gabapentin — limited evidence for withdrawal and craving
• Bupropion — not effective
• Cannabinoid agonists (nabilone, dronabinol) — used in research; not standard treatment

Medications targeting co-occurring conditions — anxiety, depression, insomnia, ADHD — are often crucial. Treating the underlying driver frequently reduces cannabis use.

Treating Co-occurring Conditions

Cannabis is frequently used to manage untreated anxiety, sleep problems, ADHD, PTSD, and chronic pain. Treating these conditions directly with evidence-based approaches often reduces cannabis use more effectively than focusing on cannabis alone.

Mutual-Help Communities

• Marijuana Anonymous
• SMART Recovery
• Cannabis-inclusive participation in AA or NA

Goal: Abstinence vs. Reduction

Either goal can be appropriate. Abstinence is often the cleanest path for severe CUD, those with psychotic vulnerability, and those whose use is tightly linked to specific harms. Reduction can be a legitimate goal for mild-to-moderate CUD, particularly when treatment of underlying conditions is also under way. The goal should be informed by clinical risk, not by stigma about cannabis.

Supporting a Loved One

What Helps

• Bring current evidence to the conversation — modern cannabis is not the cannabis of past decades
• Focus on observable consequences in the person's life
• Avoid minimizing concerns because cannabis is legal where you live
• Encourage treatment of co-occurring anxiety, depression, ADHD, insomnia, or PTSD
• If there is family history of psychotic disorders, name the risk directly

What to Avoid

• Lectures or scare tactics that ignore the user's actual experience
• Treating cannabis as a moral issue rather than a clinical one
• Drug testing as a substitute for relationship
• Believing that legality means safety

For Adolescents

Adolescent cannabis use deserves special attention because of the developmental vulnerability. Family-based interventions and CBT have evidence in this age group. Untreated anxiety, ADHD, and trauma are common drivers and should be addressed alongside cannabis use.